Anti-S1P antibody as a novel therapeutic strategy for VEGFR TKI resistant renal cancer

PURPOSE: VEGFR2 tyrosine kinase inhibition (TKI) is a valuable treatment approach for patients with metastatic RCC. However, resistance to treatment is inevitable. Identification of novel targets could lead to better treatment for both patients with TKI naïve or resistant RCC. EXPERIMENTAL DESIGN: I...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Cancer Res
Main Authors: Zhang, Liang, Wang, Xiaoen, Bullock, Andrea J., Callea, Marcella, Shah, Harleen, Song, Jiaxi, Moreno, Kelli, Visentin, Barbara, Deutschman, Douglas, Alsop, David C., Atkins, Michael B., Mier, James W., Signoretti, Sabina, Bhasin, Manoj, Sabbadini, Roger A., Bhatt, Rupal S.
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4419371/
https://ncbi.nlm.nih.gov/pubmed/25589614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2031
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki